Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 52.2% in July

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 83,534 shares, a decline of 52.2% from the June 30th total of 174,705 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average daily volume of 326,346 shares, the days-to-cover ratio is presently 0.3 days.

Dyadic International Trading Up 7.7%

Dyadic International stock traded up $0.08 during midday trading on Thursday, reaching $1.14. The stock had a trading volume of 95,246 shares, compared to its average volume of 180,349. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. Dyadic International has a 52-week low of $0.65 and a 52-week high of $1.60. The firm has a market cap of $41.61 million, a price-to-earnings ratio of -4.97 and a beta of 1.15. The company has a fifty day moving average of $0.91 and a 200 day moving average of $0.86.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. On average, analysts anticipate that Dyadic International will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyadic International

Several hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Geode Capital Management LLC lifted its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares in the last quarter. Marathon Capital Management boosted its position in Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new stake in Dyadic International in the 3rd quarter valued at about $190,000. Institutional investors own 27.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.